LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have...
Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London )
Also on site :
- 6/29: CBS Weekend News
- Watch Morgan Wallen Bring Out Surprise Guest For Sizzling Duet During Night One At Camp Randall Stadium
- Multiple firefighters shot in Idaho